Company Overview
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Why Investors Should Care
Revenue has grown at a 56.0% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $54.03M (+48.0% YoY); net profit $-412.78M.
- Trailing 12 Months Year-on-year growth — revenue +137.7%, earnings -161.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 56.0%, profit CAGR -26.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 55.97% |
| 1 Year: | 137.70% |
Compounded Profit Growth
| 5 Years: | -26.03% |
| 1 Year: | -161.27% |
Stock Price Performance
| 1 Year: | +1.76% |
| 6 Months: | +40.51% |
| 3 Months: | +20.42% |
| 1 Month: | +39.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross1d ago
- RSI (14)63.23 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 56.0% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -26.0% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AGIO Agios Pharmaceuticals, Inc. R2K | 39.92 | -5.50 | $2.37B | 0.00% | -38.86% | -32.81% | 55.97% | -26.03% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 11.36M | - | 8.76M | 40.41M | 15.20M | 30.01M | 30.23M | 26.22M | 26.02M | 35.44M | 87.10M | 37.35M | 34.71M | 44.05M | 0 | 0 | 0 | - | 832.00K | 5.58M | 3.52M | 5.61M | 6.71M | 7.40M | 8.19M | 8.62M | - | - | 8.73M | 12.46M | 12.88M | 19.97M | 20.75M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.08M | 1.70M | 1.68M | 1.88M | 1.32M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.64M | 10.75M | 11.20M | 18.09M | 19.43M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 114.27M | 137.81M | 128.07M | 139.67M | 129.45M |
| Operating Income | -40.90M | -23.59M | -56.47M | -63.51M | -57.41M | -67.05M | -84.60M | -79.02M | -90.13M | -94.01M | -72.95M | -99.16M | -96.36M | -97.48M | -113.86M | -109.06M | -105.93M | -87.03M | -83.26M | -80.29M | -92.43M | -91.22M | -91.22M | -91.15M | - | -101.14M | -97.64M | -91.09M | -90.61M | -93.70M | -100.90M | -92.07M | -105.82M | - | - | -106.63M | -127.06M | -116.87M | -121.58M | -110.03M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -105.35M | -125.80M | -115.50M | -120.31M | -108.66M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -89.29M | -112.02M | -103.43M | -109.06M | -99.11M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 53.12M | -8.88M | - | - | 0 | -1.02M | - |
| Net Income | - | -23.20M | -55.95M | -62.83M | -23.20M | -66.17M | -83.08M | -77.14M | - | -90.83M | -68.75M | -94.66M | - | -93.08M | -109.87M | -106.17M | - | -40.26M | -90.48M | -98.98M | - | 1.87B | -86.22M | -88.77M | - | -94.77M | -91.81M | -81.75M | -81.02M | -83.81M | -91.32M | -81.55M | -96.12M | - | - | -89.29M | -112.02M | -103.43M | -108.04M | -99.11M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.59 | -1.31 | -1.43 | -1.41 | 26.95 | -1.41 | -1.56 | -1.74 | -1.74 | -1.68 | -1.49 | -1.47 | -1.51 | -1.64 | -1.45 | -1.69 | 16.22 | - | -1.55 | -1.93 | -1.78 | - | -1.69 |
| R&D Expense | - | 44.04M | 50.80M | 60.64M | - | 62.73M | 79.82M | 72.92M | - | 78.22M | 86.73M | 82.56M | - | 95.58M | 107.39M | 101.67M | - | 55.36M | 54.09M | 51.94M | - | 57.67M | 62.01M | 64.00M | - | 70.12M | 74.52M | 64.97M | 67.30M | 68.89M | 81.84M | 68.62M | 77.40M | 72.45M | - | 72.74M | 91.94M | 86.80M | - | 81.15M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.84M | 25.11M | 25.55M | 65.36M | 59.12M | 69.89M | 43.01M | 94.39M | 117.91M | 0 | - | 14.24M | 26.82M | 36.50M | 54.03M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | 1.70M | 2.88M | 4.17M | 6.34M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | 12.54M | 23.94M | 32.33M | 47.68M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 401.58M | 415.43M | 458.07M | 519.82M |
| Operating Income | -16.63M | -23.00M | -38.88M | -54.13M | -118.70M | -200.99M | -320.79M | -362.48M | -316.27M | -335.92M | - | -389.05M | -391.49M | -425.74M | -472.13M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | -380.48M | -384.86M | -420.08M | -466.95M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | -231.80M | -352.09M | 717.97M | -413.80M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 44.24M | -1.02M |
| Net Income | -23.71M | -20.10M | -39.41M | -53.50M | -117.73M | -198.47M | -314.67M | -346.03M | -411.47M | -327.37M | - | -231.80M | -352.09M | 673.73M | -412.78M |
| Diluted EPS | - | - | - | - | - | - | - | - | -6.86 | -4.74 | - | -4.23 | -6.33 | 11.64 | -7.12 |
| R&D Expense | 31.25M | 41.04M | 54.50M | 100.37M | 141.83M | 220.16M | 292.68M | 341.32M | 214.26M | 220.81M | 256.97M | 279.91M | 295.53M | 301.29M | 339.54M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 137.01M | 201.21M | 491.90M | 420.06M | 619.09M | 614.40M | 858.46M | 890.74M | 852.95M | - | 1.24B | 937.12M | 1.66B | 1.30B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 832.77M | 833.84M | 965.60M | 942.05M |
| Cash & Equivalents | 77.88M | 117.66M | 91.30M | 71.56M | 14.03M | 71.76M | 160.75M | 102.72M | 70.50M | 80.93M | 127.44M | - | 139.26M | 88.20M | 76.25M | 89.13M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | 8.49M | 19.08M | 27.62M | 32.92M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 2.21M | 2.81M | 4.11M | 10.58M |
| Total Liabilities | - | - | - | - | - | - | 260.50M | 238.89M | 170.92M | 250.21M | 453.45M | - | 137.90M | 126.10M | 122.24M | 104.11M |
| Current Liabilities | - | - | 35.11M | 36.93M | 61.09M | 52.89M | 88.43M | 94.94M | 93.50M | 92.89M | 94.39M | - | 62.63M | 67.95M | 81.16M | 82.21M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | 85.66M | 72.00M | 56.99M | 40.21M |
| Total Equity | -29.59M | -52.78M | -72.02M | 131.48M | 424.37M | 345.12M | 358.59M | 375.50M | 687.54M | 640.53M | 399.50M | - | 1.10B | 811.02M | 1.54B | 1.19B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 71.26M | 72.16M | 73.37M | 74.67M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -15.22M | -49.55M | -56.40M | - | -76.95M | 38.56M | -285.23M | -304.42M | -370.62M | -290.76M | - | -309.48M | -296.06M | -389.84M | -372.98M |
| Investing Cash Flow | -22.36M | 23.04M | -87.22M | - | 128.31M | -119.35M | -57.91M | -273.82M | 91.44M | 75.75M | - | 243.26M | 239.57M | 363.44M | 377.18M |
| Financing Cash Flow | 77.36M | 142.00K | 123.88M | - | 6.37M | 169.78M | 285.11M | 546.02M | 289.61M | 261.52M | - | 2.35M | 5.43M | 14.44M | 8.68M |
| Capital Expenditure | -1.91M | -1.48M | -1.29M | -2.22M | -20.16M | -9.91M | -4.63M | -6.99M | -12.03M | -14.11M | - | -4.88M | -18.50M | -1.69M | -14.32M |
| Free Cash Flow | -17.12M | -51.02M | -57.69M | - | -97.11M | 28.65M | -289.86M | -311.41M | -382.65M | -304.87M | - | -314.36M | -314.56M | -391.53M | -387.29M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | -63.87M | -51.05M | -11.96M | 12.88M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | 88.0% | 89.3% | 88.6% | 88.3% |
| Operating Margin % | -76.2% | -91.6% | -152.2% | -82.8% | -200.8% | -287.6% | -745.8% | -384.0% | -268.2% | - | - | -2,732.1% | -1,459.5% | -1,166.5% | -873.9% |
| Net Margin % | -108.6% | -80.1% | -154.2% | -81.9% | -199.1% | -284.0% | -731.6% | -366.6% | -349.0% | - | - | -1,627.8% | -1,312.6% | 1,845.9% | -764.0% |
| ROE % | 44.9% | 27.9% | -30.0% | -12.6% | -34.1% | -55.3% | -83.8% | -50.3% | -64.2% | -81.9% | - | -21.1% | -43.4% | 43.7% | -34.6% |
| ROCE % | - | -22.6% | -23.7% | -12.6% | -32.3% | -37.9% | -61.8% | -47.4% | -39.6% | -44.3% | - | -33.1% | -45.0% | -26.9% | -38.9% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AGIO
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week
An accelerated approval for Agios' key drug to treat sickle cell disease appears to be on the cards.
Is Agios Pharmaceuticals (AGIO) A Bargain After FDA Priority Review For Mitapivat?
Agios Pharmaceuticals (AGIO) is back in focus after the US Food and Drug Administration accepted its supplemental New Drug Application for mitapivat in sickle cell disease with Priority Review and set a PDUFA decision date of November 1, 20…
Agios Pharmaceuticals (AGIO) Is Up 13.8% After FDA Grants Priority Review To Mitapivat In Sickle Cell Disease
In early July 2026, Agios Pharmaceuticals announced that the U.S. FDA had accepted its supplemental New Drug Application for mitapivat in sickle cell disease under the accelerated approval pathway and granted it Priority Review, setting a P…
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up
Agios stock jumps after the FDA accepts and grants priority review to its sNDA for mitapivat in sickle cell disease, with a decision due on Nov. 1, 2026.
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.…
Why This Novo Nordisk Rival Just Soared To A Profit-Taking Zone
Agios stock skyrocketed to a profit-taking zone Tuesday after the FDA assigned its sickle cell drug a speedy review.
AGIO — Frequently Asked Questions
What is the current share price of Agios Pharmaceuticals, Inc. (AGIO)?
As of 2026-07-14 21:23 PDT, Agios Pharmaceuticals, Inc. (AGIO) trades at $39.92 on NasdaqGS. Its 52-week range is $22.34 to $45.49.
What is the market capitalisation of AGIO?
Agios Pharmaceuticals, Inc. (AGIO) has a market capitalisation of $2.37B on NasdaqGS.
What is the P/E ratio of AGIO?
AGIO trades at a trailing price-to-earnings (P/E) ratio of -5.50. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.58.
What is the return on equity (ROE) of AGIO?
AGIO has a return on equity (ROE) of -32.81%. Its return on capital employed (ROCE) is -38.86%.
Is AGIO a good stock to buy?
This page provides a data-driven analysis of Agios Pharmaceuticals, Inc. (AGIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.